Liebert A, Quietzsch D, Beier L
Klinikum Chemnitz gGmbH, Institut für Laboratoriumsmedizin, Germany.
Anticancer Res. 1999 Jul-Aug;19(4A):2571-6.
As a matter of routine, prepared cytosols of human primary breast cancer specimens (n = 230) are analysed for both CATH D and hormone receptor status (ER,PR). Retrospectively, uPA was determined in the samples. The selection criterion for the retrospective analysis was the possibility of a longitudinal follow-up of the patients. All tumor stages were included, but the main emphasis was on lower tumor stages (T1, and T2) as well as nodal negative stages (N0). The results of the hormone receptor status (ER,PR) were: ER+PR+ 66.37%; ER+PR- 10.18%, ER-PR+ 10.18%, ER-PR- 13.27%. The CATH D results ranged from 5 to 246 pmol/mg protein. 30.97% of these results rose above 50 pmol/mg protein (positive), 42.48% were below 35 pmol/mg protein (negative). The uPA results ranged from 0.05 to 3.74 ng/mg protein. 27.43% of the uPA results rose above 0.71 ng/mg protein (positive), 58.85% were below 0.53 ng/mg protein (negative). Raised results of uPA are distinct in the higher tumor stages (T1N0 > T2N0 > T2N1 > T4Nx). Although the CATH D and uPA measurements showed similar results (positive/negative distribution) in the general survey, the confirmity of both factors is rather limited if it is focused to single cases. Between CATH D and uPA there was a confirmity of 50% (T1N0) of 45.5% (T2N0) respectively in the range of positive results, and there was a confirmity of 60.3% (T1N0) and 65.8% (T2N0), respectively, in the range of negative results. Differences were seen in 19.2% (T1N0) and 22.7% (T2N0), respectively, in the range of positive results, and in 20.6% (T1N0) in 1508% (T2N0), respectively, in the range of negative results. The prospectively diagnostic value of these is still under observation.
作为常规操作,对230例人原发性乳腺癌标本的制备胞质溶胶进行组织蛋白酶D和激素受体状态(雌激素受体、孕激素受体)分析。回顾性地测定样本中的尿激酶型纤溶酶原激活物(uPA)。回顾性分析的选择标准是患者进行纵向随访的可能性。纳入了所有肿瘤分期,但主要重点是较低肿瘤分期(T1和T2)以及无淋巴结转移分期(N0)。激素受体状态(雌激素受体、孕激素受体)的结果为:雌激素受体阳性+孕激素受体阳性66.37%;雌激素受体阳性+孕激素受体阴性10.18%,雌激素受体阴性+孕激素受体阳性10.18%,雌激素受体阴性+孕激素受体阴性13.27%。组织蛋白酶D结果在5至246 pmol/mg蛋白质之间。这些结果中30.97%高于50 pmol/mg蛋白质(阳性),42.48%低于35 pmol/mg蛋白质(阴性)。uPA结果在0.05至3.74 ng/mg蛋白质之间。uPA结果中27.43%高于0.71 ng/mg蛋白质(阳性),58.85%低于0.53 ng/mg蛋白质(阴性)。uPA升高的结果在较高肿瘤分期(T1N0 > T2N0 > T2N1 > T4Nx)中明显。尽管在总体调查中组织蛋白酶D和uPA测量显示出相似结果(阳性/阴性分布),但如果聚焦于单个病例,这两个因素的一致性相当有限。在阳性结果范围内,组织蛋白酶D和uPA之间的一致性分别为50%(T1N0)和45.5%(T2N0),在阴性结果范围内,一致性分别为60.3%(T1N0)和65.8%(T2N0)。在阳性结果范围内,差异分别为19.2%(T1N0)和22.7%(T2N0),在阴性结果范围内,差异分别为20.6%(T1N0)和15.8%(T2N0)。这些指标的前瞻性诊断价值仍在观察中。